Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

US senators launch inquiry into Big Pharma’s D2C telehealth platforms

The news: A group of US senators are concerned that new direct-to-consumer (D2C) telehealth platforms from Pfizer and Eli Lilly may be pressuring clinicians to prescribe the drugmakers’ medications.

Dick Durbin (D., Ill.) and three other senators sent letters to both Big Pharma companies. They’re requesting written responses to better understand the nature of the drug manufacturers’ relationships with contracted telehealth prescribers.

Catch up quick: Earlier this year, Eli Lilly and Pfizer rolled out websites that connect patients to third-party telehealth providers who can prescribe both pharma firms’ drugs. Consumers can also order OTC health products and get medications filled/delivered to their homes.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account